scholarly journals Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta‐analysis of seven phase III trials

2016 ◽  
Vol 18 (7) ◽  
pp. 721-724 ◽  
Author(s):  
J. Seufert ◽  
T. Bailey ◽  
S. Barkholt Christensen ◽  
M. A. Nauck
Keyword(s):  
Body Weight ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Meta Analysis ◽  
Glycated Haemoglobin ◽  
Diabetes Duration ◽  
Phase Iii ◽  
Fasting Plasma ◽  
Phase Iii Trials

scholarly journals Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: A meta-analysis

2020 ◽  
Author(s):  
Jessica Annalena Huthmacher ◽  
Juris J. Meier ◽  
Michael A. Nauck
Keyword(s):  
Body Weight ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Basal Insulin ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Short Acting ◽  
Fasting Plasma ◽  
Long Acting

<b>Background/Purpose.</b> To compare efficacy and safety of short- and long-acting GLP-1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin in patients with type 2 diabetes.<b></b> <p><b> </b></p> <p><b>Data Sources/Study Selection.</b><b><i> </i></b>Randomized controlled trials comparing the co-administration of short- or long-acting GLP-1 RAs and basal insulin with basal insulin ± placebo were identified (PubMed search). Of 974 identified publications 14 clinical trials were included. Eight trials examined short-acting and six long-acting GLP-1 RAs.<b></b></p> <p><b> </b></p> <p><b>Data Extraction/Data Synthesis.</b> Differences in HbA<sub>1c</sub>, fasting plasma glucose, body weight and adverse events were compared between studies using short- or long-acting GLP-1 RAs by random-effects meta-analysis.</p> <p><b> </b></p> <p><b>Limitations. </b>Relatively small numbers of available publications, some heterogeneity regarding protocols and differences in the GLP-1 RA compound used.</p> <p><b> </b></p> <p><b>Conclusions.</b> Long-acting GLP-1 RAs more effectively reduced HbA<sub>1c</sub> (∆ - 6 mmol/mol, [95 % CI - 10; - 2], p= 0.007), fasting plasma glucose (∆ - 0.7 mmol/l [- 1.2; - 0.3] p= 0.007) and body weight (∆ - 1.4 kg [- 2.2; - 0.6] p= 0.002) and raised the proportion of patients achieving an HbA<sub>1c</sub> target < 7.0% (< 53 mmol/mol; p= 0.03) more than the short-acting ones. Patients reporting symptomatic (p= 0.048), but not severe hypoglycemia (p= 0.96) were fewer with long- vs. short-acting GLP-1 RAs added to insulin. The proportion of patients reporting nausea (- 52 %; p < 0.0001) or vomiting (- 36 %; p= 0.0002) was lower with long-acting GLP-1 RAs.<b> </b>Overall, GLP-1 RAs improved HbA<sub>1c</sub>, fasting plasma glucose and body weight when added to basal insulin. However, long-acting GLP-1 RAs were significantly more effective for glycemic and body weight control and displayed better gastro-intestinal tolerability. </p>

scholarly journals Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

2020 ◽  
Author(s):  
Jessica Annalena Huthmacher ◽  
Juris J. Meier ◽  
Michael A. Nauck
Keyword(s):  
Body Weight ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Basal Insulin ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Short Acting ◽  
Fasting Plasma ◽  
Long Acting

<b>Background/Purpose.</b> To compare efficacy and safety of short- and long-acting GLP-1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin in patients with type 2 diabetes.<b></b> <p><b> </b></p> <p><b>Data Sources/Study Selection.</b><b><i> </i></b>Randomized controlled trials comparing the co-administration of short- or long-acting GLP-1 RAs and basal insulin with basal insulin ± placebo were identified (PubMed search). Of 974 identified publications 14 clinical trials were included. Eight trials examined short-acting and six long-acting GLP-1 RAs.<b></b></p> <p><b> </b></p> <p><b>Data Extraction/Data Synthesis.</b> Differences in HbA<sub>1c</sub>, fasting plasma glucose, body weight and adverse events were compared between studies using short- or long-acting GLP-1 RAs by random-effects meta-analysis.</p> <p><b> </b></p> <p><b>Limitations. </b>Relatively small numbers of available publications, some heterogeneity regarding protocols and differences in the GLP-1 RA compound used.</p> <p><b> </b></p> <p><b>Conclusions.</b> Long-acting GLP-1 RAs more effectively reduced HbA<sub>1c</sub> (∆ - 6 mmol/mol, [95 % CI - 10; - 2], p= 0.007), fasting plasma glucose (∆ - 0.7 mmol/l [- 1.2; - 0.3] p= 0.007) and body weight (∆ - 1.4 kg [- 2.2; - 0.6] p= 0.002) and raised the proportion of patients achieving an HbA<sub>1c</sub> target < 7.0% (< 53 mmol/mol; p= 0.03) more than the short-acting ones. Patients reporting symptomatic (p= 0.048), but not severe hypoglycemia (p= 0.96) were fewer with long- vs. short-acting GLP-1 RAs added to insulin. The proportion of patients reporting nausea (- 52 %; p < 0.0001) or vomiting (- 36 %; p= 0.0002) was lower with long-acting GLP-1 RAs.<b> </b>Overall, GLP-1 RAs improved HbA<sub>1c</sub>, fasting plasma glucose and body weight when added to basal insulin. However, long-acting GLP-1 RAs were significantly more effective for glycemic and body weight control and displayed better gastro-intestinal tolerability. </p>

scholarly journals Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

2020 ◽  
Author(s):  
Jessica Annalena Huthmacher ◽  
Juris J. Meier ◽  
Michael A. Nauck
Keyword(s):  
Body Weight ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Basal Insulin ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Short Acting ◽  
Fasting Plasma ◽  
Long Acting

<b>Background/Purpose.</b> To compare efficacy and safety of short- and long-acting GLP-1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin in patients with type 2 diabetes.<b></b> <p><b> </b></p> <p><b>Data Sources/Study Selection.</b><b><i> </i></b>Randomized controlled trials comparing the co-administration of short- or long-acting GLP-1 RAs and basal insulin with basal insulin ± placebo were identified (PubMed search). Of 974 identified publications 14 clinical trials were included. Eight trials examined short-acting and six long-acting GLP-1 RAs.<b></b></p> <p><b> </b></p> <p><b>Data Extraction/Data Synthesis.</b> Differences in HbA<sub>1c</sub>, fasting plasma glucose, body weight and adverse events were compared between studies using short- or long-acting GLP-1 RAs by random-effects meta-analysis.</p> <p><b> </b></p> <p><b>Limitations. </b>Relatively small numbers of available publications, some heterogeneity regarding protocols and differences in the GLP-1 RA compound used.</p> <p><b> </b></p> <p><b>Conclusions.</b> Long-acting GLP-1 RAs more effectively reduced HbA<sub>1c</sub> (∆ - 6 mmol/mol, [95 % CI - 10; - 2], p= 0.007), fasting plasma glucose (∆ - 0.7 mmol/l [- 1.2; - 0.3] p= 0.007) and body weight (∆ - 1.4 kg [- 2.2; - 0.6] p= 0.002) and raised the proportion of patients achieving an HbA<sub>1c</sub> target < 7.0% (< 53 mmol/mol; p= 0.03) more than the short-acting ones. Patients reporting symptomatic (p= 0.048), but not severe hypoglycemia (p= 0.96) were fewer with long- vs. short-acting GLP-1 RAs added to insulin. The proportion of patients reporting nausea (- 52 %; p < 0.0001) or vomiting (- 36 %; p= 0.0002) was lower with long-acting GLP-1 RAs.<b> </b>Overall, GLP-1 RAs improved HbA<sub>1c</sub>, fasting plasma glucose and body weight when added to basal insulin. However, long-acting GLP-1 RAs were significantly more effective for glycemic and body weight control and displayed better gastro-intestinal tolerability. </p>

Use of high-normal levels of haemoglobin A1Cand fasting plasma glucose for diabetes screening and for prediction: a meta-analysis

2013 ◽  
Vol 29 (8) ◽  
pp. 680-692 ◽  
Author(s):  
Satoru Kodama ◽  
Chika Horikawa ◽  
Kazuya Fujihara ◽  
Reiko Hirasawa ◽  
Yoko Yachi ◽  
...  
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Meta Analysis ◽  
Diabetes Screening ◽  
Fasting Plasma

scholarly journals Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort

2015 ◽  
Vol 44 (6) ◽  
pp. 1927-1940 ◽  
Author(s):  
Marine Azevedo Da Silva ◽  
Aline Dugravot ◽  
Beverley Balkau ◽  
Ronan Roussel ◽  
Frédéric Fumeron ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Cell Function ◽  
Glycated Haemoglobin ◽  
Β Cell ◽  
Fasting Plasma ◽  
Β Cell Function ◽  
Antidepressant Use

Abstract Background : Use of antidepressants is seen to be a risk factor for type 2 diabetes, even though the underlying mechanisms remain unclear. We examined whether antidepressant use was associated with change in fasting plasma glucose, glycated haemoglobin (HbA1c), β-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) over time. Methods : Participants in the French D.E.S.I.R. cohort study included over 4700 men (48.1%) and women, free of diabetes, aged 30–65 years at baseline in 1994–96 (D.E.S.I.R. 0), who were followed for 9 years at 3-yearly intervals (D.E.S.I.R. 3, 1997–99; 6, 2000–02; 9, 2003–05). Antidepressant use, fasting plasma glucose, HbA1c, HOMA2-%B and HOMA2-%S were assessed concurrently at four medical examinations. Linear mixed models were used to examine the cross-sectional and longitudinal associations of time-dependent antidepressant use with changes in these four biological parameters. Results : Mean fasting plasma glucose and HbA1c increased whereas HOMA2-%B and HOMA2-%S decreased over the follow-up. In a fully adjusted model, there were no differences in: mean fasting plasma glucose ( β  = 0.01 mmol/l, P  = 0.702); HbA1c ( β  = 0.01 %, P  = 0.738); HOMA2-%B ( β  = 0.00, P  = 0.812); or HOMA2-%S ( β  =−0.01, P  = 0.791) at baseline (1994–96) between antidepressant users and non-users. The interaction term with time also suggested no differences in the annual change in: fasting plasma glucose ( β  = 0.00 mmol/l, P  = 0.322); HbA1c ( β  = 0.00 %, P  = 0.496); HOMA2-%B ( β  = 0.00, P  = 0.609); or HOMA2-%S ( β  = 0.00, P  = 0.332) between antidepressant users and non-users. Similar associations were observed in analyses of type and cumulative use of antidepressants over follow-up. Conclusion : Our longitudinal data show that use of antidepressants is not associated with altered glucose metabolism, suggesting that the association between antidepressant use and diabetes reported by previous studies may not be causal. Detection bias or clinical ascertainment bias may account for much of this apparent association.

Sign in / Sign up

Export Citation Format

Share Document